FDA requests further safety data from Eli Lilly on Foundayo's liver injury risks

Eli Lilly's weight loss drug Foundayo faces increased scrutiny as the FDA demands additional safety information, highlighting ongoing safety challenges. This escalation occurs despite the drug's recent approval and positive trial results, emphasizing the importance of post-market surveillance. Watch for Lilly's response and the potential impact on the drug's market availability and labeling.